834 related articles for article (PubMed ID: 23389892)
1. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
3. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
5. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Dobesh PP; Fanikos J
Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
7. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Klauser W; Dütsch M
Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Prandoni P; Temraz S; Taher A
Semin Hematol; 2014 Apr; 51(2):121-30. PubMed ID: 24861796
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
11. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
12. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Dempfle CE
Semin Hematol; 2014 Apr; 51(2):89-97. PubMed ID: 24861792
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants: An update.
Franco Moreno AI; Martín Díaz RM; García Navarro MJ
Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
[TBL] [Abstract][Full Text] [Related]
15. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
King CS; Holley AB; Moores LK
Chest; 2013 Apr; 143(4):1106-1116. PubMed ID: 23546483
[TBL] [Abstract][Full Text] [Related]
16. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
18. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Yeh CH; Gross PL; Weitz JI
Blood; 2014 Aug; 124(7):1020-8. PubMed ID: 24923298
[TBL] [Abstract][Full Text] [Related]
19. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
20. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Wong PC; Crain EJ; Watson CA; Xin B
J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
